FDA Approves New ADC for HR+, HER2- Breast Cancer

Source link : https://www.newshealth.biz/health-news/fda-approves-new-adc-for-hr-her2-breast-cancer/

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Specifically, the novel Trop-2-directed antibody and topoisomerase inhibitor conjugate is indicated for those who have received prior treatment with endocrine-based therapy and […]

Author : News Health

Publish date : 2025-01-17 22:15:24

Copyright for syndicated content belongs to the linked Source.